SynthesisJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.
Synthesis in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Platelet activation and eicosanoid signaling in ovarian cancer: implications for biomarker development.Molecular biology reports · 2026Review
- A Multistate Survival Model to Identify Risk Factors for Lethal Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Modifiable Lifestyle and Environmental Determinants of Ovarian Cancer Risk: Implications for Primary Prevention.Healthcare (Basel, Switzerland) · 2026Review
- Longer-term aspirin use and subsequent ovarian cancer risk in the Ovarian Cancer Cohort Consortium.International journal of epidemiology · 2026Article
- Hereditary cancer syndromes with gynecological cancer risk: focus on prevention strategies.Frontiers in oncology · 2026Review
- Ovarian cancer risk prediction: a clinical epidemiology perspective.American journal of epidemiology · 2025Article
- Sympathetic nerve signaling rewires the tumor microenvironment: a shift in "microenvironmental-ity".Cancer metastasis reviews · 2025Review
- Aspirin in Cancer Therapy: Pharmacology and Nanotechnology Advances.International journal of nanomedicine · 2025Review
- Sulindac exhibits anti-proliferative and anti-invasive effects and enhances the sensitivity to paclitaxel in ovarian cancer.Frontiers in pharmacology · 2025Article
- The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study.BMC medicine · 2024Article
- Prevention of Ovarian Cancer: Where are We Now and Where are We Going?Current oncology reports · 2024Review
- Article
- Exploring Aspirin's Potential in Cancer Prevention: A Comprehensive Review of the Current Evidence.Cureus · 2024Review
- Contraception as chemoprevention of ovarian cancer in BRCA1 and BRCA2 women.Hormones (Athens, Greece) · 2024Review
- Global epidemiology of epithelial ovarian cancer.Nature reviews. Clinical oncology · 2024Review
- Low-dose aspirin use and risk of ovarian cancer: a combined analysis from two nationwide studies in Denmark and Sweden.British journal of cancer · 2024Article
- Association of COX-inhibitors with cancer patients' survival under chemotherapy and radiotherapy regimens: a real-world data retrospective cohort analysis.Frontiers in oncology · 2024Article
- Sexually Transmitted Infections and Risk of Epithelial Ovarian Cancer: Results From the Finnish Maternity Cohort.The Journal of infectious diseases · 2023Article
- Association of Frequent Aspirin Use With Ovarian Cancer Risk According to Genetic Susceptibility.JAMA network open · 2023Article
- Highlighting the value of Alzheimer's disease-focused registries: lessons learned from cancer surveillance.Frontiers in aging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 20 institutions in 4 countries.
Funding
Abstract
purposeFrequent aspirin use has been associated with reduced ovarian cancer risk, but no study has comprehensively assessed for effect modification. We leveraged harmonized, individual-level data from 17 studies to examine the association between frequent aspirin use and ovarian cancer risk, overall and across subgroups of women with other ovarian cancer risk factors.
methodsNine cohort studies from the Ovarian Cancer Cohort Consortium (n = 2,600 cases) and eight case-control studies from the Ovarian Cancer Association Consortium (n = 5,726 cases) were included. We used Cox regression and logistic regression to assess study-specific associations between frequent aspirin use (≥ 6 days/week) and ovarian cancer risk and combined study-specific estimates using random-effects meta-analysis. We conducted analyses within subgroups defined by individual ovarian cancer risk factors (endometriosis, obesity, family history of breast/ovarian cancer, nulliparity, oral contraceptive use, and tubal ligation) and by number of risk factors (0, 1, and ≥ 2).
resultsOverall, frequent aspirin use was associated with a 13% reduction in ovarian cancer risk (95% CI, 6 to 20), with no significant heterogeneity by study design (
conclusionThis study, the largest to-date on aspirin use and ovarian cancer, provides evidence that frequent aspirin use is associated with lower ovarian cancer risk regardless of the presence of most other ovarian cancer risk factors. Risk reductions were also observed among women with multiple risk factors, providing proof of principle that chemoprevention programs with frequent aspirin use could target higher-risk subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.